One Little Baxalta(BXLT) Spark Of Corporate Gobbledygook

Baxalta(BXLT) completed its spinoff from Baxter International(BAX) yesterday. Or, as Baxalta would have it “Baxalta Launches as a Global Biopharmaceutical Leader Dedicated to Patients with Orphan Diseases and Underserved Conditions.”  Baxalta is no slouch, what with “New products and indications planned to contribute $2.5 billion in sales by 2020, building on base of $6 billion in annual revenue.”… Read More »